Clinical Trial Update: Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Ongoing Phase 1/2 clinical trial evaluating mezigdomide in combination with elranatamab for relapsed/refractory multiple myeloma; the study is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elranatamab (elranatamab)
• Mezigdomide (mezigdomide)

Snippet

Sponsor: YOUNGIL KOH | Conditions: Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1, Phase 2 | Status: RECRUITING